EP2981271
Lækningaleg notkun empagliflozin
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.4.2014EP published:
14.11.2018EP application number:
14715578.2
EP translation filed:
14.1.2019Grant published:
15.2.2019EPO information:
European Patent Register
Max expiry date:
2.4.2034Expiry date:
2.4.2026Next due date:
30.4.2026
Title:
THERAPEUTIC USES OF EMPAGLIFLOZIN
Timeline
Today
3.4.2014EP application
14.11.2018EP Publication
14.1.2019Translation submitted
15.2.2019Registration published
2.4.2026Expires
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, 55216, Ingelheim am Rhein, DE
Inventor
Name:
BROEDL, UliAddress:
Ingelheim am Rhein, DE
Name:
VON EYNATTEN, MaximilianAddress:
Ingelheim am Rhein, DE
Name:
MACHA,SreerajAddress:
Ridgefield, Connecticut, US
Name:
WOERLE, Hans-JuergenAddress:
Ingelheim am Rhein, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361808804 PDate:
5.4.2013Country:
US
Number:
2812519Date:
10.4.2013Country:
CA
Number:
201361908991 PDate:
26.11.2013Country:
US
Classification
Categories:
A61K 31/7048, A61P 3/10, A61P 13/12
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 12.4.2019
Expires: 2.4.2020
Payer: Tego ehf.
Number: 7
Paid: 31.3.2020
Expires: 2.4.2021
Payer: Tego ehf.
Number: 8
Paid: 12.4.2021
Expires: 2.4.2022
Payer: G.H. Sigurgeirsson ehf.
Number: 9
Paid: 12.4.2022
Expires: 2.4.2023
Payer: G.H. Sigurgeirsson ehf.
Number: 10
Paid: 11.4.2023
Expires: 2.4.2024
Payer: G.H. Sigurgeirsson ehf.
Number: 11
Paid: 12.4.2024
Expires: 2.4.2025
Payer: G.H. Sigurgeirsson ehf.
Number: 12
Paid: 10.4.2025
Expires: 2.4.2026
Payer: G.H. Sigurgeirsson ehf.